Dry Eye – Unmet Need – Unmet Need – Dry Eye Disease US/EU

Dry eye disease (DED), also known as keratoconjunctivitis sicca, is a chronic, multifactorial, and highly heterogeneous ophthalmic condition that negatively affects patient’s vision and quality of life. The signs and symptoms of DED vary widely among patients, making its management challenging. Beyond conservative measures like lid hygiene and over-the-counter artificial tears, the U.S. DED therapy market includes FDA-approved therapies such as AbbVie’s Restasis, Bausch + Lomb’s Xiidra, Bausch + Lomb / Novaliq’s Miebo, Harlow’s Vevye, and Viatrist’s Tyrvaya. The European market has fewer approved therapies (e.g., cyclosporin anti-inflammatory eyedrops, Santen’s Ikervis, Thea’s Vevizye). Despite these approved options, multiple off-label therapies, including antibiotics and corticosteroids, remain central to managing DED. Understanding the factors that influence physicians’ treatment decisions and identifying the greatest areas of unmet need in DED treatment will be crucial for the strategic positioning of novel agents in this market.

QUESTIONS ANSWERED

• What are the most important factors driving ophthalmologists’ prescribing decisions for DED?
• How do DED therapies perform on key clinical attributes?
• What are the prevailing areas of unmet need in DED treatment?
• What trade-offs are surveyed ophthalmologists willing to make across key clinical attributes and price for a new therapy for DED?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.